Table 2.
Antagonist | pA2 (+95% CL) | Slope (+95% CL) | Slope constrained pA2 (+95% CL) |
---|---|---|---|
Naltrexone s.c. | 8.9 (5.1–13) | −0.72 (−1.9 to 0.48) | 8.3 (7.6–9.0) |
+1.0 μg CTAP | 6.6 (6.4–6.8) | −3.7c (−6.0 to −1.4) | —d |
+10 μg CTAP | 7.3 (5.0–9.7) | −0.88 (−3.6 to 1.9) | 7.3 (6.9–7.7) |
+1 μg Naltrexone | 8.6a | —d | —d |
CTAP i.c.v. | 9.0 (2.6–15) | −0.80 (−6.0 to 4.4) | 8.8 (8.2–9.4) |
+0.1 mg kg−1 naltrexone | 9.7b | −0.46 | —d |
CTOP i.c.v. | 8.9 | −1.54 | —d |
+Naltrexone and CTAP | 9.5a | —d | —d |
Apparent pKB calculation using a dose of antagonist or antagonist combination.
Apparent pA2 and slope values determined using only two dose–response curves.
Slope significantly different than naltrexone s.c. in the presence of 10 μg CTAP i.c.v.
Value cannot be determined.